Good morning,
Welcome to today’s edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
For every drug development company, there is one slide that never changes.
The M&A transaction slide.
Past deals. Big numbers. Lots of logos.
But I always wondered… those transactions happened in the past. What's the likelihood they continue into the future? Is the potential actually as big as the company says?
Sometimes, the universe just answers that question for you.
This morning, I woke up to the news that Sanofi will pay US$135 million upfront, and up to US$1.53 billion in milestones.
This was for a JAK/ROCK inhibitor pill approved last month for Myelofibrosis in China.
(Source, Pharmaceutical Technology)
Literally just yesterday, I wrote about Syntara (ASX: SNT) and its lead asset for exactly that disease (Myelofibrosis).
In case you missed it: Three Shots, One Strategy: The Syntara (ASX: SNT) Story
A key part of the story was that three Myelofibrosis assets had been bought for US$1.7 billion and US$2.9 billion, respectively.
Well, we can add a fourth one to that list now…
The M&A slide just updated itself.
Thanks senrindipity.
The Pulse Check
LTR Pharma (ASX: LTP) completes recruitment for its Phase II SPONTAN® erectile dysfunction clinical study. Results next quarter. (LTP)
🪑 With the trial coming up, it might be a good time to revisit my article on the company, particularly the section “How will LTP commercialise its product?”.
Yesterday, Nexalis Therapeutics (ASX: NX1) commences Phase 1 trial for inhaled CBD treatment for panic disorder. (NX1)
🪑 These guys are the old InhalerX
Pacific Edge (ASX: PEB) secures the first order of its Cxbladder Triage Plus test from Townsville University Hospital. (PEB)
🪑 Adoption is one of the key pillars for any diagnostics company.
Good start, let’s see if PEB can maintain the momentum.
TrivarX (ASX: TRI) terminates its Chief Medical Officer, signalling a move away from “sleep for mental health” and towards its new asset, Stabl-Im, a metastatic brain imaging technology. (TRI)
Osteopore (ASX: OSX) signs an 18-month collaboration agreement with Tan Tock Seng Hospital to develop a novel implant for avascular necrosis (AVN) treatment. (OSX)
🪑 Every time the noteholder is issued shares, the company releases news. I’m being careful of this one.
Droplet Biosciences published a new case study with the NVIDA’s Parabricks GPU, which ‘drastically speeds up genomic data analysis for DNA sequencing’. (Fierce Biotech)
🪑 AI for healthcare, drug development and diagnostics is a HUGE market for NVIDIA. I expect technology to advance at an incredibly fast rate. Disruptions are coming.
Cash Injection
Entropy Neurodynamics (ASX: ENP) receives $1.73M from the Australian Government's R&D Tax rebate. (ENP)
M&A, Big Pharma Wants a Wife
Sanofi will pay US$135M upfront and up to US$1.53B in milestones for a JAK/ROCK inhibitor pill approved last month for Myelofibrosis in China. (Pharmaceutical Technology)
🪑 Great news for ASX-listed Syntara (ASX: SNT). It essentially reaffirms the price for its myelofibrosis lead asset (if it can take it through to a Phase 3). US$1.53 billion.
UCB enters the T-Cell Engager space with a US$1.1B deal for aChinese biotech's autoimmune candidate. (Fierce Biotech)
See you all tomorrow,
The Armchair Analyst
